Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
CAS NO.314771-88-5
A(1-2)Kilogram
Inner Mongolia Yong Ming Technology Co.,Ltd--- a worthy to be depended and trusted Pharmaceutical Intermediates company. We make sure the good quality product and reasonable price. We have the good after-sales service, to solve any kinds of problems, the goal is making every customer satisfy with our company and gain the best reputation.
There are variety of products for your choose. Please contact with us at any time.
Our promise:
1. Good quality product and reasonable price~ make customers happy and save customers’ money
2. Delivery product on time~ save customers’ time
3. Professional packing~let the customers receive it successfully
4. Many payment instruments~convenient to pay
5. Service customers forever~ to establish long-term cooperation relationship
Welcome to your inquire and suggestions, everyone here do the best for you!
Product name: N-(3-chloro-4-fluorophenyl)-6-nitro-7-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine
CAS number: 314771-88-5
Application: the intermediates of Afatinib
Delivery time: within 1-3 days after the payment
Pharmacodynamics and pharmacokinetics editor:
Imatinib is an oral drug that is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinase. B/ phase III randomized study II showed that compared with placebo plus best supportive care, afatinib + best supportive treatment previously failed second-line chemotherapy and EGFR-TKI treatment of patients with non-small cell lung cancer, did not improve overall survival, but significantly improved progression free survival, increased ORR and 8 weeks of disease control rate. Another study (LUX-LUNG2) showed that most patients (61%) with common EGFR mutations had significantly reduced tumor size, advanced tumor progression, and longer survival after receiving treatment with imatinib. These results initially confirm that sunitinib is a promising target drug.
Please feel free to contact with us for any reuirements by email/skype: gina@alpine-ltd.com
Welcome to your inquire, thanks in advance.
More information: mona@nmg-ym.com
Skype: live:mona_3363